Aardvark Therapeutics Inc

AARDNASDAQ · USD
5.38USD0.00 (-2.72%)
2310

Aardvark Therapeutics Inc (AARD) Option Chain

As of September 18, 2026, Aardvark Therapeutics Inc is trading at $5.38, a -2.72% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 176.3%. IV Rank is —%.

Read more

Tracking the AARD option chain helps you see every strike and expiry on Aardvark Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Aardvark Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AARD options activity at a glance. Use our scanner to monitor the AARD option chain in real time and filter for the AARD options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AARD stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the AARD option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where AARD stock options are being actively traded and where they are not.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.

It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Aardvark Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen AARD options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of AARD stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile
  • Market cap (M$)118
  • 52 weeks high-70.01%
  • 52 weeks low60.60%
  • Analyst recommendationBuy
    2.36
  • Target price$10.12
    88.10% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-12
  • P/E
  • Future P/E
  • EPS (ttm)-3.21
  • EPS growth next 5 years5.48%

As of September 18, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
8.73000.102.880.555.402.50-53.534.900.004.900091.27
53.28001.620.382.005.00-7.064.900.004.900046.72
82.24004.900.004.907.50+39.410.104.902.120.380017.76
93.60004.900.004.9010.00+85.872.507.004.620.13006.40
97.65004.900.004.9012.50+132.345.009.507.120.13002.35

As of September 18, 2026

Scan the full option chain in one place

Browse the full AARD option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial